Form 8-K - Current report:
SEC Accession No. 0001213900-25-032119
Filing Date
2025-04-15
Accepted
2025-04-15 16:23:44
Documents
14
Period of Report
2025-04-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0238436-8k_aditxt.htm   iXBRL 8-K 29459
2 CALL OPTION AGREEMENT BY AND AMONG ADITXT, INC., ADJUVANT GLOBAL HEALTH TECHNOLO ea023843601ex10-1_aditxt.htm EX-10.1 57085
  Complete submission text file 0001213900-25-032119.txt   276256

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE adtx-20250410.xsd EX-101.SCH 3008
4 XBRL LABEL FILE adtx-20250410_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE adtx-20250410_pre.xml EX-101.PRE 22354
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0238436-8k_aditxt_htm.xml XML 3784
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39336 | Film No.: 25839777
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)